trending Market Intelligence /marketintelligence/en/news-insights/trending/qNszSzT6y7VcflslsJbeMw2 content esgSubNav
In This List

60° Pharmaceuticals seeks US FDA approval for preventive malaria medication

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


60° Pharmaceuticals seeks US FDA approval for preventive malaria medication

60° Pharmaceuticals LLC is seeking approval from the U.S. Food and Drug Administration for Tafenoquine for the prevention of malaria in adults.

The company entered into a cooperative research and development agreement with the U.S. Army Medical Materiel Development Activity in 2014 for the development of the drug.

Tafenoquine has been studied in more than 30 clinical trials involving more than 4,000 participants.